Sanguine Bioscience, a California-based biotechnology company focused on patient recruitment, sample collection engagement and digital health, has partnered with multiple biotech and pharmaceutical companies, such as Vir Biotechnology and EpiVax, Inc, to facilitate the patient recruitment for over 23 research studies, studies aimed at gaining a better understanding of COVID-19.
As a chronic autoimmune disease, patients with systemic lupus erythematosus (SLE) experience widespread inflammation and unpredictable disease flare episodes that progressively worsen over time, contributing to tissue and organ damage. Its heterogeneous nature, slow disease progression, and seemingly random symptom flares complicate research studies aimed at improving therapeutic options for SLE patients.
Hepatitis B virus (HBV) is the world’s most common cause of chronic viral infection. Individuals may become infected through contact with bodily fluids or from mother to child during birth. Some people with acute HBV infections experience symptoms like vomiting, yellowish skin, dark urine, fatigue, and abdominal pain, while others feel no symptoms at all.
The broad spectrum of clinical manifestations seen in systemic lupus erythematosus (SLE) makes it challenging to characterize the disease meaningfully. Particularly problematic for researchers and physicians alike is the apparent classification of differences between acute episodes and chronic disease damage. To that end, the SLE disease activity index (SLEDAI-2K) functions to standardize the assessment of disease severity by clinicians globally.